Home Cart Sign in  
Chemical Structure| 1211877-36-9 Chemical Structure| 1211877-36-9

Structure of (R)-MG-132
CAS No.: 1211877-36-9

Chemical Structure| 1211877-36-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(R)-MG132 can act as an inhibitor of proteasome and be used in ubiquitination assay.

Synonyms: (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al; MG132

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (R)-MG-132

CAS No. :1211877-36-9
Formula : C26H41N3O5
M.W : 475.62
SMILES Code : [C@H](NC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(C)C)=O)(C(N[C@@H](CC(C)C)C=O)=O)CC(C)C
Synonyms :
(S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al; MG132
MDL No. :MFCD28580122

Safety of (R)-MG-132

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • Proteasome

    Proteasome, IC50:100 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
mouse brain synaptosomes 10 µM 30 min To investigate the effects of proteasome inhibition on presynaptic architecture and function, results showed that MG132 treatment significantly reversed the structural defects in RIM1α KO synapses and restored release probability to WT levels. PMC3664715
HEI-193 schwannoma cells 2.5 μM 24, 48, 72 h To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the proliferation of schwannoma cells. Results showed that MG-132 enhanced the inhibitory effect of Nutlin-3 on cell proliferation. PMC6197711
RT4-D6P2T schwannoma cells 2.5 μM 24, 48, 72 h To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the proliferation of schwannoma cells. Results showed that MG-132 enhanced the inhibitory effect of Nutlin-3 on cell proliferation and narrowed the sensitivity differences between cells with different merlin expression status. PMC6197711
Naïve CD4+ T cells 10 µM 2 h Promote CD69+ iTregs differentiation PMC10091886
RVSMCs 10 μM 6 days Treatment with MG132 or lactacystin halved Pi-induced calcium deposition, demonstrating proteasome inhibition alleviates vascular calcification PMC4740400
A10 cells (RVSMC line) 10 μM 4 h MG132 treatment enhanced HDAC1 ubiquitination under Pi stimulation, confirming HDAC1 degradation via the proteasomal pathway PMC4740400
rat vascular smooth muscle cells (RVSMCs) 10 μM 4 h MG132 markedly attenuated Pi-induced HDAC1 reduction, indicating proteasomal inhibition prevents HDAC1 degradation PMC4740400
Plasmodium falciparum 3D7 parasite-infected red blood cells 100 nM 72 h Inhibition of 26S proteasome activity significantly inhibited α-spectrin degradation and parasite proliferation PMC11005373

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice RT4-D6P2T and HEI-193 schwannoma xenograft models Intraperitoneal injection 5 mg/kg Once daily for 14 days To evaluate the inhibitory effect of MG-132 combined with Nutlin-3 on the growth of schwannoma xenografts. Results showed that the combined treatment significantly inhibited tumor growth and induced apoptosis of tumor cells. PMC6197711
Mice DSS-induced colitis model Intraperitoneal injection 15 μM/kg 9 days Promote CD69+ Tregs differentiation but fail to effectively alleviate colitis PMC10091886
Mice VD3-induced vascular calcification model Intraperitoneal injection 2.5 mg/kg Daily administration for 9 days MG132 significantly reduced VD3-induced aortic calcium deposition and prevented HDAC1 downregulation PMC4740400
Mouse P23H mice Intraperitoneal injection 5 mg/kg Single injection To enhance the detection of ubiquitinated proteins PMC6639359
C57BL/6 mice Plasmodium berghei ANKA infection model Intraperitoneal injection 1.5 mg/kg Once daily for 9 days Inhibition of 26S proteasome activity significantly reduced parasitemia PMC11005373
Mice Vitamin D receptor knockout mice Intraperitoneal injection 2.5 mg/kg Once daily for 2 days To assess protein ubiquitination levels, results showed higher total ubiquitination and K48-linked ubiquitination in skeletal muscles of vdr /C0//C0 mice. PMC8818613
Mice Healthy mice Intraperitoneal injection 10 μg/kg Single injection, samples collected after 24 hours MG-132, as a proteasome inhibitor, was used to study the effect of agmatine on β-catenin stability. Results showed that agmatine increased β-catenin stability by suppressing Rnf128-mediated ubiquitination degradation. PMC11086030
Mice Wildtype mice Intraperitoneal injection 50µg/g Single injection, analyzed after 3 hours MG132 significantly increased VEGF receptor levels in type H vessel columns PMC5580829

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.51mL

2.10mL

1.05mL

21.03mL

4.21mL

2.10mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories